Interventional cardiology devices are mainly used for diagnosing and treating cardiovascular diseases. These devices are mainly used by hospitals, clinics, and academic research institutes.

The interventional cardiology devices market is segmented into angioplasty balloons, angioplasty stents, catheters, plaque modification devices, hemodynamic flow alteration devices, and accessories.

Factors driving the growth of this market include rising geriatric population, improving healthcare infrastructure, and increasing incidence of CVD. On the other hand, the stringent regulatory scenario for these devices and the availability of effective first-line treatments is expected to limit market growth in the coming years. The interventional cardiology devices market is expected to reach USD 20.85 billion by 2022 from USD 14.52 billion in 2017, at a CAGR of 7.5%.

�The plaque modification devices segment is anticipated to grow at the fastest rate during the forecast period.�

The plaque modification devices market, by type, is categorized into thrombectomy devices and atherectomy devices. The thrombectomy devices segment is estimated to grow at the fastest rate during the forecast period. The increasing demand for technologically advanced thrombectomy devices is a key factor driving the growth of this market.

�The angioplasty stent market segment is estimated to hold the largest market share during the forecast period.�

The angioplasty stents market is segmented drug-eluting stents, bare-metal stents, and bioresorbable stents. The bioresorbable stents segment is the fastest-growing segment of the global angioplasty stents market. Technological advancement in stents is driving the growth of this segment.

�The normal balloons segment is projected to dominate the angioplasty balloons market during the forecast period�

In 2017, the old/normal balloons segment is expected to account for the largest share of the angioplasty balloons market. The drug-eluting balloons segment, on the other hand, is expected to register the highest CAGR of 6.8% during the forecast period. The high growth rate can be attributed to the anti-proliferative drug coating on drug-eluting stents, which helps in overcoming complications, such as late thrombosis, associated with the drug-eluting stent (DES) procedure and rising number of regulatory approvals for drug-eluting balloons.

�Asia Pacific is estimated to grow at the highest CAGR during the study period.�

Geographically, the interventional cardiology devices market is dominated by North America, followed by Europe in 2017. Asia Pacific is estimated to grow at the fastest rate, due to infrastructural development in its healthcare systems, the rising burden of CVD, and increasing healthcare expenditure in APAC countries.

Market Dynamics

Driver: Technological advancements in interventional cardiology devices

With developments in technology, effective, advanced, simple, and easy-to-use interventional cardiology devices are being launched in the market. The use of imaging and diagnostic technologies such as IVUS (intravascular ultrasound) and OCT (optical coherence tomography) has brought significant changes in the usage pattern of diagnostic techniques. These devices show significant promise in terms of guidance in treatment and diagnosis of cardiovascular diseases. Increasing attention on interventional cardiology, mainly due to the growing demand for advanced devices and services, has driven research into these systems. In addition, the growing emphasis on the effective, accurate, and early treatment of target diseases is driving the number of industry-academia collaborations aimed at the development and commercialization of innovative and therapeutically diverse products.

Opportunity: Bioresorbable vascular scaffolds/bioresorbable stents

Bioabsorbable stents are expected to seize a significant market share in the coming years, as they are capable of reducing postsurgical risks associated with restenosis to a great extent. Moreover, their bioabsorbable nature leaves no permanent scaffold within the vessel. This minimizes the risk of late-stent thrombosis post angioplasty. Offerings in this market include advanced products such as the bioresorbable DESolve scaffold (Tiny Elixir Medical Corporation) and the Absorb bioresorbable stent (Abbott) were approved in 2014 and 2016 respectively. Increasing attention to ascertaining their safety and efficacy, given their benefits and the approvals of new bioresorbable stents, will provide opportunities for players in the market focusing on this segment.

Scope of the Report

Report Metric Details Market size available for years 2015�2022 Base year considered 2017 Forecast period 2017�2022 Forecast units Value (USD) Segments covered Market based on products such as angioplasty balloons, angioplasty stents, catheters, plaque modification devices, hemodynamic flow alteration devices, other interventional cardiology devices and sub-types Geographies covered North America (US and Canada), Europe (Germany, France, UK, and RoE), APAC (Japan, China, India, and RoAPAC), and South America (Brazil, Argentina and Rest of South America) and Middle East and Africa (GCC and South Africa, Rest of Middle East and Africa) Companies covered Major 10 players covered, including:

Boston Scientific Corporation (Boston Scientific) (US), Abbott Laboratories (Abbott) (US), Medtronic Public Limited Company (Medtronic) (US), Cordis Corporation (Cordis) (US), Terumo Corporation (Terumo) (Japan), B. Braun (Germany), C.R. Bard (US), Biosensors (Singapore), Ivascular (Spain) and BIOTRONIK (Germany).

The research report categorizes the Interventional Cardiology Devices market into the following segments and subsegments:

By Type:

Angioplasty Balloons Old/Normal Balloons Cutting and Scoring Balloons Drug-Eluting Balloons

Angioplasty Stents Drug-Eluting Stents Bare-Metal Stents Bioabsorbable Stents

Stents Catheters Angiography Catheters Market Ivus/Oct Catheters Market Guiding Catheters Market

Plaque Modification Devices Thrombectomy Devices Atherectomy Devices

Hemodynamic Flow Alteration Devices Embolic Protection Devices Chronic Total Occlusion Devices

Other Interventional Cardiology Devices Guidewires Vascular Closure Devices Introducer Sheaths Balloon Inflation Devices



By Region

North America US Canada

Europe Germany France UK Italy Spain Rest of Europe

Asia Pacific Japan China India Rest of Asia Pacific

Latin America

Middle East and Africa

Key Market Players

Recent Developments

Product Launches

Year Company Name Segment Product 2017 Abbott Instruments XIENCE Sierra, coronary stent system 2017 Medtronic Equipment Onyx Drug-Eluting Stent (DES) 2016 Abbott Equipment Absorb, Bioresorbable Stent 2015 Boston Scientific Instruments SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System

Critical questions the report answers:

Where will all these developments take the industry in the long term?

What are the upcoming trends for the interventional cardiology market?

Which segment provides the most opportunity for growth?

Who are the leading vendors operating in this market?

What are the opportunities for new market entrants?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst